HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience.


INTRODUCTION Most of the cost-effectiveness analyses are based on estimations to make decisions on the future implementation of a test. However, the model should be verified with real data to prove that previous estimations have been successfully fulfilled. OBJECTIVE To study the economic impact of the systematic HLA-B*57:01 genotyping in preventing… (More)
DOI: 10.1097/FPC.0000000000000229


6 Figures and Tables